Clinical Efficacy And Safety Of Apatinib In The Treatment Of Advanced Lung Cancer

Objective: To observe the clinical efficacy and adverse reaction of apatinib in the treatment of advanced lung cancer.Methods: This was a retrospective study on 42 patients with advanced lung cancer.The patients received oral apatinib 250-500 mg per day as the second and above line until disease progression or intolerable toxicity.Results: Among the 42 patients with advanced lung cancer,19 cases were treated with apatinib combined with chemotherapy,23 cases were treated with apatinib alone.The median progression-free survival(mPFS)of the total patients was 4.4 months,objective response rate(ORR)16.7%,and disease control rate(DCR)76.2%.The ORR was higher in the combined treatment group compared with the single apatinib group(31.6%vs 4.3%).The DCR was also higher in the combined group(94.7% vs56.5%).Similarly,apatinib combination group prolonged median PFS compared with single group(5.6months vs 4.0 months).Univariate analysis showed that ECOG performance status 0-1 was correlated with prolonged median PFS and improved DCR(P<0.05).Common adverse reactions include hypertension,hand and foot syndrome,gastrointestinal reaction,oral ulcer,bleeding.Most of the adverse reactions were grade 1-2,which were alleviated after symptomatic treatment.Conclusion: Apatinib as a second-line or laterline therapy is effective and well tolerated for patients with advanced lung cancer.and its combination with chemotherapy is more effective in the treatment of lung cancer.